Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A01044 | Pages: 180 | Charts: 57 | Tables: 126 |
The global biosurgery market was valued at $11,425.49 million in 2020, and is projected to reach $27,324.80 million by 2030, growing at a CAGR of 9.1% from 2021 to 2030. Biosurgery is defined as the procedure used in various surgeries to minimize the intra and post-operative complications. Various synthetic and biologic products, such anti-adhesive agents, hemostatic agents, surgical sealing agents, bone graft substitutes, and soft tissue management are used in surgeries for prevention of excessive blood loss and to repair the damaged or weakened tissues or bones of body. These advanced biosurgery products enhance the work efficiency of physicians by controlling surgery-related difficulties in expensive and complicated surgeries.
The global biosurgery market size is expected to increase substantially in the near future, owing to high investment by governments and private organizations in the medical device sector, increase in spending on R&D activities by researchers, and aggressive strategies adopted by top players such as new product launches. Growth of the global biosurgery market share is majorly driven by increase in prevalence of chronic disease, rise in demand for elective surgeries, increase in funding from private & government organizations for development of healthcare infrastructure, and increase in number of geriatric population.
Increase in prevalence of severe traumatic injuries drives the growth of the biosurgery market share, as the rise in number of traumatic injuries increases the demand for biosurgery products. In addition, presence of key manufacturing companies to manufacture advanced biosurgery products contributes toward the biosurgery market growth. Moreover, increase in prevalence of geriatric population, who are more susceptible to chronic diseases, propels growth of the biosurgery market opportunity.
Furthermore, advancement in R&D activities in pharmaceutical sector and development of medical device sector is expected to provide lucrative opportunities for expansion of the global biosurgery market during the forecast period. Moreover, increase in number of surgical procedures and rise in number of sports-related injuries propel the growth of the biosurgery industry.
Initiatives taken by government and private organizations to develop the medical device industry drive the growth of the biosurgery industry. However, high cost of biosurgery products and stringent regulations are expected to restrict the market growth during the biosurgery market forecast.
The biosurgery market size is segmented into product type, application, source, and region. Depending on product type, the market is divided into anti-adhesive agents, hemostatic agents and surgical sealants, bone graft substitutes, and mesh (soft tissue management). On the basis of application, the market is segmented into cardiovascular and thoracic, neuro and spine surgery, orthopedic surgery, and general surgery. On the basis of source, the market is segmented into biologics products and synthetic products.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Depending on product type, the bone graft substitutes segment was the highest contributor to the market in 2020, and this trend is expected to continue during the forecast period, due to surge in demand for bone graft substituent products and increase in number of sports injuries and surgeries.
However, the anti-adhesive agents segment is expected to witness considerable growth during the forecast period, owing to increase in incidence of surgeries, such as cardiovascular surgery and general abdominal surgery, which surge the need for anti-adhesive agents in the biosurgery market.
[PRODUCTTYPEGRAPH]
By application, the neuro and spine surgery segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of neurological disorder. However, the general surgery segment is expected to witness considerable growth during the forecast period, owing to increase in incidence of surgeries, rise in sedentary lifestyle, and increase in geriatric population.
[APPLICATIONGRAPH]
On the basis of source, the biologics products segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in demand for natural products and rise in technological development in the pharmaceutical sector.
However, the synthetic products segment is expected to witness considerable growth during the forecast period, owing to advancement in R&D activities for manufacturing of various products for the surgery.
[SOURCEGRAPH]
North America dominated the biosurgery market in 2020, and is expected to be dominant during the forecast period, owing to rise in prevalence of chronic disease, increase in number of surgery, presence of key players for manufacturing biosurgery products, and rise in development in R&D activities in the healthcare sector. However, Asia-Pacific is expected to register highest CAGR of 10.2% from 2021 to 2030, owing to increase in number of geriatric population, rise in number of sport related surgery and injury, and increase in demand for biosurgery products.
[REGIONGRAPH]
The major companies profiled in this report include, Aroa Biosurgery Limited, B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Hemostasis LLC, Integra LifeSciences Holdings Corp., Johnson and Johnson, Medtronic PLC, Sanofi S.A., and Tissue Regenix Group.
Key Market Segments
Key Market Players